SLC5A2 and cardiac arrhythmia: The pooled results demonstrated a reduction in the incidence of arrhythmia in patients treated with SGLT2 inhibitors, in comparison to the control group (RR 0.34, 95% CI 0.23, 0.50, P < 0.0001, I2 = 0%) (Figure 4A).